Skip to content
Agree.net – Lifestyle
Author:
Nasdaq, Inc.
BioMarin Provides Update on Phase 3 Trial for BMN 401 in Children Aged 1-12 With ENPP1 Deficiency
May 18, 2026
Nasdaq Announces 2026 Annual Meeting of Shareholders
May 14, 2026
BioMarin Presents New Data on the Effect of Long-Term Treatment with VOXZOGO® (vosoritide) on Arm Span, Bone Health and Growth in Children With Achondroplasia at the Pediatric Endocrine Society’s 2026 Annual Meeting
May 14, 2026
Delisting of Securities from The Nasdaq Stock Market
May 11, 2026
Lumentum Holdings Inc. to Join the Nasdaq-100 Index® Beginning May 18, 2026
May 8, 2026
Nasdaq Reports April 2026 Volumes
May 5, 2026
BioMarin Reports First Quarter 2026 Financial and Operating Results
May 5, 2026
Nasdaq to Match Federal Contribution to Trump Accounts for Employees’ Children
April 29, 2026
BioMarin Completes Acquisition of Amicus Therapeutics
April 27, 2026
Nasdaq Resumes Trading in American Rebel Holdings, Inc.
April 27, 2026
←
Previous Page
1
…
4
5
6
7
8
Next Page
→